North America Epilepsy Drugs Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$4,849.8

Forecast, 2030 (US$M)

$6,710.5

CAGR, 2024 - 2030

4.7%

Report Coverage

North America

North America epilepsy drugs market, 2018-2030 (US$M)

Related Markets

Global Epilepsy Drugs Industry Outlook

Europe Epilepsy Drugs Market Outlook

Asia Pacific Epilepsy Drugs Market Outlook

Latin America Epilepsy Drugs Market Outlook

MEA Epilepsy Drugs Market Outlook

North America epilepsy drugs market highlights

The North America epilepsy drugs market generated a revenue of USD 4,849.8 million in 2023.
The market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
In terms of segment, first generation anti-epileptics was the largest revenue generating product in 2023.
First Generation Anti-epileptics is the most lucrative product segment registering the fastest growth during the forecast period.

North America data book summary

Market revenue in 2023	USD 4,849.8 million
Market revenue in 2030	USD 6,710.5 million
Growth rate	4.7% (CAGR from 2023 to 2030)
Largest segment	First generation anti-epileptics
Fastest growing segment	First Generation Anti-epileptics
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	First Generation Anti-epileptics
Key market players worldwide	UCB SA, Sanofi SA, Pfizer Inc, Otsuka Pharmaceutical, Eisai Co Ltd, Abbott Laboratories, Novartis AG ADR, GlaxoSmithKline, Sumitomo Pharma Co Ltd, Neurelis, Jazz Pharmaceuticals PLC

Other key industry trends

In terms of revenue, North America region accounted for 44.6% of the global epilepsy drugs market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 2,941.2 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Epilepsy Drugs Market Scope

Epilepsy drugs market segmentation & scope

Product

First Generation Anti-epileptics

Second Generation Anti-epileptics

Third Generation Anti-epileptics

Regions

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Countries

U.S.

Canada

Germany

France

Italy

Spain

Switzerland

Netherlands

Denmark

Sweden

Norway

Japan

China

India

Australia

South Korea

Indonesia

Thailand

Mexico

Brazil

South Africa

Saudi Arabia

UAE

Kuwait

Argentina

Epilepsy Drugs Market Companies

Name	Profile	# Employees	HQ	Website

North America epilepsy drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epilepsy drugs market will help companies and investors design strategic landscapes.

First generation anti-epileptics was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America epilepsy drugs market based on first generation anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to North America epilepsy drugs market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America epilepsy drugs market databook

Our clientele includes a mix of epilepsy drugs market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America epilepsy drugs market , including forecasts for subscribers. This continent databook contains high-level insights into North America epilepsy drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list